Alpha DNA Investment Management LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)


Share on StockTwits

Alpha DNA Investment Management LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 271 shares of the pharmaceutical company’s stock, valued at approximately $64,000.

A number of other institutional investors have also modified their holdings of the business. Michael B. Yongue grew its holdings in Vertex Pharmaceuticals by 6.0% during the 4th quarter. Michael B. Yongue now owns 868 shares of the pharmaceutical company’s stock worth $205,000 after acquiring an additional 49 shares during the period. Bailard Inc. grew its stake in shares of Vertex Pharmaceuticals by 2.8% in the 4th quarter. Bailard Inc. now owns 2,191 shares of the pharmaceutical company’s stock valued at $518,000 after buying an additional 59 shares during the period. EFG Asset Management Americas Corp. grew its stake in shares of Vertex Pharmaceuticals by 4.9% in the 4th quarter. EFG Asset Management Americas Corp. now owns 1,287 shares of the pharmaceutical company’s stock valued at $304,000 after buying an additional 60 shares during the period. Eudaimonia Partners LLC grew its stake in shares of Vertex Pharmaceuticals by 22.5% in the 3rd quarter. Eudaimonia Partners LLC now owns 332 shares of the pharmaceutical company’s stock valued at $90,000 after buying an additional 61 shares during the period. Finally, Hellman Jordan Management Co. Inc. MA grew its stake in shares of Vertex Pharmaceuticals by 8.2% in the 4th quarter. Hellman Jordan Management Co. Inc. MA now owns 924 shares of the pharmaceutical company’s stock valued at $218,000 after buying an additional 70 shares during the period. Hedge funds and other institutional investors own 92.17% of the company’s stock.

VRTX opened at $212.72 on Thursday. The company has a fifty day moving average price of $213.50 and a 200-day moving average price of $226.85. The firm has a market capitalization of $55.30 billion, a P/E ratio of 26.86, a price-to-earnings-growth ratio of 1.25 and a beta of 0.79. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.72 and a quick ratio of 3.60. Vertex Pharmaceuticals Incorporated has a one year low of $202.57 and a one year high of $306.08.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Sunday, January 31st. The pharmaceutical company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $2.59 by ($0.08). Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same quarter last year, the firm earned $1.70 earnings per share. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 8.5 earnings per share for the current year.

Several analysts have recently commented on the company. HC Wainwright reduced their target price on Vertex Pharmaceuticals from $315.00 to $275.00 and set a “buy” rating for the company in a research note on Tuesday, February 2nd. SVB Leerink reduced their target price on Vertex Pharmaceuticals from $257.00 to $250.00 and set a “market perform” rating for the company in a research note on Tuesday, February 2nd. BMO Capital Markets reduced their target price on Vertex Pharmaceuticals from $302.00 to $284.00 and set an “outperform” rating for the company in a research note on Tuesday, February 2nd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 11th. Finally, Credit Suisse Group lowered their price target on shares of Vertex Pharmaceuticals from $285.00 to $280.00 and set an “outperform” rating on the stock in a report on Tuesday, February 2nd. Four analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $293.13.

In other Vertex Pharmaceuticals news, EVP Bastiano Sanna sold 1,686 shares of the business’s stock in a transaction on Thursday, February 11th. The shares were sold at an average price of $210.56, for a total value of $355,004.16. Following the completion of the sale, the executive vice president now directly owns 39,081 shares of the company’s stock, valued at $8,228,895.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Parini sold 400 shares of the business’s stock in a transaction on Wednesday, February 3rd. The stock was sold at an average price of $216.56, for a total transaction of $86,624.00. Following the completion of the sale, the executive vice president now directly owns 35,276 shares of the company’s stock, valued at $7,639,370.56. The disclosure for this sale can be found here. Insiders sold 7,200 shares of company stock valued at $1,533,052 over the last quarter. 0.70% of the stock is owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.

Recommended Story: What does an outperform rating mean?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.